EPOGEN® (EPOETIN ALFA) RECOMBINANT

Documentation Checklist

Proper documentation includes recording the following in the medical record†:

- ☐ Most Recent Hb/Hct (include date)
- ☐ Target Hb/Hct*
- ☐ Rationale for target Hb/Hct*
- ☐ Current EPOGEN® dose
- ☐ Documentation for each dose change
- ☐ New EPOGEN® dose (if change required)
- ☐ Rationale for new EPOGEN® dose (if change required)
- ☐ Medical justification for patients whose physicians recommend Hb >12 g/dL*
- ☐ Each EPOGEN® dose given, including nurse signature and title
- ☐ **Physician's order with signature and date for each dose change†**

If EPOGEN® dose is 10,000 units or higher, document the following additional information in narrative form†

- ☐ Patient's weight
- ☐ Current EPOGEN® dose required
- ☐ Historical record of EPOGEN® given
- ☐ Hb/Hct response to date
- ☐ Iron indices
- ☐ Concomitant conditions such as infection, inflammation, malignancy, or secondary hyperparathyroidism
- ☐ Blood loss, hemolysis, bone marrow dysplasia
- ☐ Refractory anemia due to nonrenal conditions (eg,aluminum toxicity)
- ☐ Vitamin deficiencies
- ☐ Compromised bone marrow
- ☐ Concomitant medications

†These are general guidelines for appropriate documentation. Additional documentation may be required. For specific requirements that may vary by geographical region, please check with local regulatory and reimbursement agencies.

EPOGEN® is indicated for the treatment of anemia in patients with chronic renal failure on dialysis. Patients who receive EPOGEN® may experience adverse effects such as hypertension or flu-like symptoms.
*The EPOGEN® package insert recommends a target Hb (Hct) of 10 to 12 g/dL (30% to 36%).
The NKF - K/DOQI™ guidelines recommend a target Hb (Hct) of 11 to 12 g/dL (33% to 36%).